Cardiovascular & Gastrointestinal

Key areas of partnering interest

Diabetes and Obesity

Oral diabetes segment

- Insulin sensitisers
- Glucose dependent insulin secretagogues (oral GLP-1, PTP-1b)
- Beta cell protection/regeneration
- Compounds should have beneficial or neutral effect on other CV risk factors, including body weight 

Step-change insulins and management

- Non-injectable administration (oral, inhalation or transdermal)
- Non-invasive glucose monitoring 

Injectable diabetes segment

- Beta cell protection/regeneration
- Glycaemic control and weight loss

Obesity

- Novel mechanism for weight loss/prevention of weight gain including appetite and/or energy expenditure
- Early stage opportunities with proof of concept in pre-clinical models
- Good safety profile

Atherosclerosis

Technical/Discovery

- Biochemical markers, imaging technologies and relevant animal models to study the vulnerable plaque

Target Areas

- Reversed cholesterol transport by increasing ApoA1, HDL or other relevant mechanism
- Anti-inflammatory compounds relevant to plaque stability (adhesion molecules)
- Parental compounds for high risk atherosclerosis patients (i.e. ApoA1 mimetics)

Thrombosis

Anti-coagulation

- Factor Xa programmes with a predictable effect base on low variability in PK/PD  

Anti-platelets

- Improved efficacy especially for ACS patients
- Predictable action
- Rapid onset and offset

Other Cardiovascular Area

Oral atrial fibrillation agents with clinical proof of concept

Gastrointestinal

Treatments in Gastroesophageal reflux disease other than acid secretion inhibition
Novel treatments of GI diseases that have passed clinical concept testing

Contacts

Anna Rosengren